TSE:4502Pharmaceuticals
The Bull Case For Takeda Pharmaceutical (TSE:4502) Could Change Following New Zasocitinib Phase 3 Psoriasis Data
In July 2026, Takeda presented new Phase 3 data showing its oral TYK2 inhibitor zasocitinib improved skin clearance in adults with moderate-to-severe plaque psoriasis, including hard-to-treat areas like the scalp, nails, palms and soles.
By highlighting high response rates in these high-impact sites while minimizing interaction with other JAK family members, zasocitinib underscores Takeda’s push to differentiate in immunology with targeted, oral therapies.
With zasocitinib’s Phase 3 results...